23 Feb 2026 | 5 Mins Read
Novo Nordisk shares plunge 13% on drug shortfall
Flipitmoney
Novo Nordisk's shares fell 13% in US pre-market trading and 12.9% in Europe after its experimental obesity drug CagriSema failed to meet weight-loss expectations, with 23% weight loss compared to 25.5% for Eli Lilly's tirzepatide. Novo plans additional studies, including higher-dose combinations, as competition intensifies in the obesity drug market.